Pharma news
Pharma
A Netherlands court ruling marks the latest win as Novo Nordisk ramps up efforts to protect semaglutide from unapproved products, copycats and an increasingly competitive market. 6 August 2026
Regulation & Industry
From advising pioneering startups to championing women in the profession, Fran Salisbury of Mewburn Ellis has spent her career making innovation count. Here, she reflects on the challenges, opportunities and motivations that continue to drive her. 5 August 2026
Careers
With more than 25 years’ experience, the ex-EIP partner specialises in technology and life sciences, particularly SEPs and FRAND in the UK and Europe. 5 August 2026
Pharma
A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence. 31 July 2026
Regulation & Industry
Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come? 29 July 2026
Regulation & Industry
With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last? 27 July 2026
Regulation & Industry
Generic drug manufacturers face huge penalties if they fail to relocate production to the US within two years, with India among the countries expected to be hardest hit. 23 July 2026
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens. 23 July 2026
Regulation & Industry
Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture. 17 July 2026
Biotech
French drugmaker's Translate Bio unit accuses COVID rivals of infringing core lipid nanoparticle and mRNA purification patents, seeking damages from vaccines worth billions. 15 July 2026